Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMANASDAQ:DYNNASDAQ:NUVLNASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$20.42+1.3%$20.64$9.35▼$25.67$4.87B0.573.70 million shs1.32 million shsDYNDyne Therapeutics$11.69-1.8%$10.32$6.36▼$47.45$1.33B1.191.64 million shs1.47 million shsNUVLNuvalent$73.49+0.4%$71.38$55.54▼$113.51$5.26B1.42489,493 shs359,038 shsPCVXVaxcyte$32.54-4.2%$38.53$27.66▼$121.06$4.20B1.271.37 million shs1.76 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+1.29%+3.71%-6.17%+28.91%+112.05%DYNDyne Therapeutics-1.76%-1.18%+8.39%-16.56%-62.92%NUVLNuvalent+0.36%+0.23%+1.07%-7.55%+5.26%PCVXVaxcyte-4.15%+2.17%-1.87%-59.19%-54.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics3.3664 of 5 stars2.64.00.00.04.22.51.9DYNDyne Therapeutics3.4769 of 5 stars4.52.00.00.03.14.20.0NUVLNuvalent2.4646 of 5 stars3.52.00.00.03.13.30.0PCVXVaxcyte3.1041 of 5 stars4.62.00.00.03.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.25Buy$24.2518.76% UpsideDYNDyne Therapeutics 3.07Buy$47.25304.19% UpsideNUVLNuvalent 2.90Moderate Buy$115.5057.16% UpsidePCVXVaxcyte 3.10Buy$136.50319.48% UpsideCurrent Analyst Ratings BreakdownLatest DYN, NUVL, ADMA, and PCVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$46.00 ➝ $38.005/9/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.005/8/2025ADMAADMA BiologicsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.004/22/2025PCVXVaxcyteCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight4/8/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$90.00 ➝ $90.004/1/2025PCVXVaxcyteThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$138.00 ➝ $100.004/1/2025PCVXVaxcyteBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$157.00 ➝ $137.004/1/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $90.003/31/2025PCVXVaxcyteEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/21/2025DYNDyne TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$18.00 ➝ $17.003/17/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$459.38M10.61$0.07 per share311.70$0.60 per share34.03DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/ANUVLNuvalentN/AN/AN/AN/A$10.94 per shareN/APCVXVaxcyteN/AN/AN/AN/A$13.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics-$28.24M$0.8572.9329.59N/A17.80%53.20%26.07%N/ADYNDyne Therapeutics-$235.94M-$3.59N/AN/AN/AN/A-57.46%-51.62%8/11/2025 (Estimated)NUVLNuvalent-$126.22M-$4.39N/AN/AN/AN/A-28.63%-27.15%N/APCVXVaxcyte-$402.27M-$3.99N/AN/AN/AN/A-23.53%-22.20%8/5/2025 (Estimated)Latest DYN, NUVL, ADMA, and PCVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PCVXVaxcyte-$1.02-$1.04-$0.02-$1.04N/AN/A5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/8/2025Q1 2025NUVLNuvalent-$1.14-$1.18-$0.04-$1.18N/AN/A5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 million3/4/2025Q4 2024DYNDyne Therapeutics-$0.92-$0.88+$0.04-$0.88N/AN/A2/27/2025Q4 2024NUVLNuvalent-$1.03-$1.05-$0.02-$1.05N/AN/A2/25/2025Q4 2024PCVXVaxcyte-$1.16-$1.02+$0.14-$1.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.487.093.26DYNDyne TherapeuticsN/A17.0217.02NUVLNuvalentN/A23.0723.07PCVXVaxcyteN/A17.8817.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%DYNDyne Therapeutics96.68%NUVLNuvalent97.26%PCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.50%DYNDyne Therapeutics20.77%NUVLNuvalent12.52%PCVXVaxcyte3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million227.64 millionOptionableDYNDyne Therapeutics100113.67 million80.63 millionOptionableNUVLNuvalent4071.60 million62.16 millionOptionablePCVXVaxcyte160129.00 million120.77 millionOptionableDYN, NUVL, ADMA, and PCVX HeadlinesRecent News About These CompaniesFrazier Life Sciences Management L.P. Trims Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)May 23 at 7:51 AM | marketbeat.comMillennium Management LLC Sells 21,857 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)May 23 at 4:09 AM | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) is Windsor Advisory Group LLC's 4th Largest PositionMay 22 at 6:18 AM | marketbeat.comWoodline Partners LP Increases Stake in Vaxcyte, Inc. (NASDAQ:PCVX)May 22 at 6:17 AM | marketbeat.comProShare Advisors LLC Purchases 11,729 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)May 22 at 4:35 AM | marketbeat.comNuveen Asset Management LLC Acquires 65,713 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)May 22 at 4:25 AM | marketbeat.comSoleus Capital Management L.P. Buys 72,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)May 21 at 8:08 AM | marketbeat.com279,944 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Twinbeech Capital LPMay 21 at 6:47 AM | marketbeat.comMan Group plc Buys 127,875 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)May 21 at 5:05 AM | marketbeat.comPoint72 Asset Management L.P. Has $20.55 Million Position in Vaxcyte, Inc. (NASDAQ:PCVX)May 20, 2025 | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)May 20, 2025 | marketbeat.comRafferty Asset Management LLC Increases Position in Vaxcyte, Inc. (NASDAQ:PCVX)May 19, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Bank of America Corp DEMay 18, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Polar Capital Holdings PlcMay 17, 2025 | marketbeat.comParadigm Biocapital Advisors LP Has $116.47 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)May 16, 2025 | marketbeat.comParkman Healthcare Partners LLC Decreases Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)May 16, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Stock Holdings Lifted by Nicholas Investment Partners LPMay 16, 2025 | marketbeat.comContrasting Vaxcyte (NASDAQ:PCVX) & Molecular Partners (NASDAQ:MOLN)May 16, 2025 | americanbankingnews.comLazard Asset Management LLC Purchases Shares of 486,764 Vaxcyte, Inc. (NASDAQ:PCVX)May 15, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires New Stake in Vaxcyte, Inc. (NASDAQ:PCVX)May 15, 2025 | marketbeat.com98,739 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Hudson Bay Capital Management LPMay 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?3 Mid-Cap Medical Stocks Outperforming the MarketBy Ryan Hasson | May 6, 2025View 3 Mid-Cap Medical Stocks Outperforming the MarketAfter Earnings Beats, These 3 Stocks Are on Analysts’ RadarsBy Leo Miller | May 20, 2025View After Earnings Beats, These 3 Stocks Are on Analysts’ RadarsStrategists Say Hold: Stocks May Beat the 'Sell in May' TrendBy Jeffrey Neal Johnson | May 9, 2025View Strategists Say Hold: Stocks May Beat the 'Sell in May' TrendWingstop Stock Jumps on Q1 Beat, Expansion OutlookBy Jeffrey Neal Johnson | May 4, 2025View Wingstop Stock Jumps on Q1 Beat, Expansion OutlookDYN, NUVL, ADMA, and PCVX Company DescriptionsADMA Biologics NASDAQ:ADMA$20.42 +0.26 (+1.29%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$20.42 +0.00 (+0.02%) As of 05/23/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Dyne Therapeutics NASDAQ:DYN$11.69 -0.21 (-1.76%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$11.68 0.00 (-0.04%) As of 05/23/2025 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Nuvalent NASDAQ:NUVL$73.49 +0.26 (+0.36%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$73.52 +0.03 (+0.05%) As of 05/23/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Vaxcyte NASDAQ:PCVX$32.54 -1.41 (-4.15%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$32.99 +0.45 (+1.38%) As of 05/23/2025 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
